Significantly reduces the cost and complexity of pharmacovigilance
enabling organizations to focus on improving patient safety
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
IQVIA™
(NYSE:IQV) today announced its development of a Software as a Service
(SaaS) safety platform that scales to address the drug safety and
surveillance challenges of life sciences organizations, ranging from
emerging biopharma to large pharmaceutical companies. This SaaS solution
is built to allow access from multiple users, across multiple locations
and will run on the Salesforce
architecture, the global leader in CRM and provider of SaaS solutions.
“Drug safety organizations are burdened with outdated technology that is
inflexible and costly to maintain,” said Joe Rymsza, vice president,
Pharmacovigilance and Regulatory Technology Solutions at IQVIA. “Our
safety platform will leverage IQVIA’s industry knowledge and advanced
analytics to provide a step-change in operations and will allow our
customers to focus on the critical task of improving patient safety.”
IQVIA’s multi-tenant safety platform will combine IQVIA’s deep domain
expertise, three thousand plus drug safety professionals, and innovative
process automation, machine learning and artificial intelligence
technologies, with IQVIA’s real world and regulatory data to deliver
actionable insights and streamline pharmacovigilance operations.
A fundamental addition for IQVIA Technologies, the SaaS platform will
eliminate the need for costly upgrade projects and long validation
cycles. By leveraging automation to eliminate the costly and repetitive
manual processes associated with pharmacovigilance, organizations will
be able to evolve to zero-touch processing.
“IQVIA is strategically committed to providing our customers with
comprehensive pharmacovigilance technology and operational services,”
said Tal Rosenberg, senior vice president, Global Technology Solutions
at IQVIA. “This safety platform adds a transformative dimension to our
molecule-to-market technology suite.”
Additional information about IQVIA’s safety platform is available at www.iqvia.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
the information that helps their customers drive human health outcomes
forward. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap into a
deeper understanding of diseases, human behaviors and scientific
advances, in an effort to advance their path toward cures. To learn
more, visit www.iqvia.com.
IQVIAFIN
Click
here to subscribe to Mobile Alerts for IQVIA.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190108005472/en/
Tor Constantino
IQVIA Media Relations
tor.constantino@iqvia.com
+1.484.567.6732
Andrew Markwick
IQVIA Investor Relations
andrew.markwick@iqvia.com
+1.973.257.7144
Source: IQVIA